Market Research Logo

North America Alzheimer’s Disease Therapeutics And Diagnostics Market Forecast 2018-2026

North America Alzheimer’s Disease Therapeutics And Diagnostics Market Forecast 2018-2026

KEY FINDINGS

Driven by increasing prevalence of Alzheimer's in countries like the US and Canada, the North America Alzheimer’s disease therapeutics and diagnostics market is projected to rise with a CAGR of 7.47% during the forecast years of 2018-2026.

MARKET INSIGHTS

The market is chiefly segmented on the basis of diagnostics and therapeutics. According to Alzheimer’s Association, one in every 3 adults in the United States dies with Alzheimer’s or another dementia. As a result, there is a huge demand for Alzheimer’s disease therapeutics and diagnostics market in this country. Also,the National Institute of Health is funding major research projects concerning Alzheimer’s disease, which is further augmenting the growth of Alzheimer’s disease therapeutics & diagnostics market in the country. However, by the end of the projected years, the highest CAGR in the North American region is expected from Canada. According to Alzheimer society Canada, the government of Canada spends around $xx million through the Canadian Institutes of Health Research (CIHR) every year for the research operation aiming to curb this disease.

COMPETITIVE INSIGHTS

Companies like Axon Neuroscience Se, Cognoptix Inc, Biogen Inc, F. Hoffmann-La Roche Ag, Siemens Medical Solutions, Pfizer Inc, Piramal Enterprises Ltd, Baxter International Inc, Diagenic Asa, Sun Pharma, Amarantus Bioscience Holdings Inc, Abbvie Inc and Ge Healthcare are engaged in this market.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Computed Tomography Is Majorly Used In The Diagnostics Of Alzheimer’s Disease
3.2.2. Therapeutics Market Constitutes The Largest Market Share
4. Market Determinants
4.1. Market Drivers
4.1.1. Growing Geriatric Population
4.1.2. Rise In The Pervasiveness Of Alzheimer’s Disease
4.1.3. Increasing Healthcare Expenditure
4.1.4. Government Investment In Research And Development
4.2. Market Restraints
4.2.1. Stringent Government Regulations
4.2.2. High Cost Of Therapies Used For The Treatment Of Alzheimer’s Disease
4.3. Market Opportunities
4.3.1. Advancements In In-vitro Diagnostic Techniques
4.3.2. Increasing R&D Investment In The Personalized Medicines
4.4. Market Challenges
4.4.1. Lack Of Skilled Medicinal Practitioners Fot The Treatment Of Alzheimer’s Disease
4.4.2. Dearth Of Awareness Concerning New Therapies In The Alzheimer’s Disease
5. Market Segmentation
5.1. Market By Therapeutics And Diagnostic 2018-2026
5.1.1. Therapeutics
5.1.1.1. Therapeutics By Drugs
5.1.1.1.1. Marketed Drugs
5.1.1.1.2. Pipeline Drugs
5.1.1.2. Therapeutics By Disease Stage
5.1.1.2.1. Late Stage: Severe Ad
5.1.1.2.2. Early/Middle Stage: Mild To Moderate Ad
5.1.1.2.3. Prodromal Stage
5.1.1.3. Therapeutics By Generic And Branded
5.1.1.3.1. Branded
5.1.1.3.2. Generic
5.1.2. Diagnostics
5.1.2.1. Lumbar Puncture Test
5.1.2.2. Positron Emission Tomography
5.1.2.3. Electroencephalography
5.1.2.4. Magnetic Resonance Imaging
5.1.2.5. Computed Tomography
5.1.2.6. Other Diagnostics
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Threats Of Substitute Product
6.1.3. Bargaining Power Of Buyer
6.1.4. Bargaining Power Of Supplier
6.1.5. Intensity Of Competitive Rivalry
6.2. Key Buying Criteria
6.2.1. Price
6.2.2. Efficiency
6.2.3. Safety
6.3. Etymology Of Alzheimer’s Disease Therapeutics And Diagnostics Market
6.4. Parent Market Analysis
6.5. Investments Analysis
6.5.1. Research And Development
6.5.2. Raw Materials
6.5.3. Manufacturing
6.5.4. Wholesalers
6.5.5. End User
6.6. Regulatory Framework
6.7. The United States Regulatory Agency
6.8. Alzheimer's Disease Etiology
6.9. Phases And Sternness Of Alzheimer’s Disease
6.10. Pipeline Analysis
6.11. Companion Diagnostics
7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
8. Company Profiles
8.1. Competitive Landscape
8.1.1. Market Share Analysis
8.2. Abbvie Inc.
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.3. Scot Analysis
8.2.4. Strategic Initiatives
8.3. Amarantus Bioscience Holdings, Inc.
8.3.1. Company Overview
8.3.2. Product Portfolio
8.3.3. Scot Analysis
8.3.4. Strategic Initiatives
8.4. Axon Neuroscience Se
8.4.1. Company Overview
8.4.2. Product Portfolio
8.4.3. Scot Analysis
8.4.4. Strategic Initiative
8.5. Baxter International Inc.
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.3. Scot Analysis
8.6. Biogen Inc.
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.3. Scot Analysis
8.6.4. Strategic Initiatives
8.7. Cognoptix Inc.
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.3. Scot Analysis
8.7.4. Strategic Initiatives
8.8. Diagenic Asa
8.8.1. Company Overview
8.8.2. Product Portfolio
8.8.3. Scot Analysis
8.9. F. Hoffmann-la Roche Ag
8.9.1. Company Overview
8.9.2. Product Portfolio
8.9.3. Scot Analysis
8.9.4. Strategic Initiatives
8.10. Ge Healthcare
8.10.1. Company Overview
8.10.2. Product Portfolio
8.10.3. Scot Analysis
8.10.4. Strategic Initiatives
8.11. Merck And Co.
8.11.1. Company Overview
8.11.2. Product Portfolio
8.11.3. Scot Analysis
8.11.4. Strategic Initiatives
8.12. Pfizer Inc.
8.12.1. Company Overview
8.12.2. Product Portfolio
8.12.3. Scot Analysis
8.12.4. Strategic Analysis
8.13. Piramal Enterprises Ltd.
8.13.1. Company Overview
8.13.2. Product Portfolio
8.13.3. Scot Analysis
8.13.4. Strategic Initiatives
8.14. Siemens Medical Solutions
8.14.1. Company Overview
8.14.2. Product Portfolio
8.14.3. Scot Analysis
8.14.4. Strategic Initiatives
8.15. Sun Pharma
8.15.1. Company Overview
8.15.2. Product Portfolio
8.15.3. Scot Analysis
8.15.4. Strategic Initiatives
Table List
Table 1 North America Alzheimer’s Disease Therapeutics And Diagnostics Market 2018-2026 ($ Million)
Table 2 Pharmacological Treatment Of Behavioral And Psychological Symptoms Of Dementia (Bpsd) Of Alzheimer's
Table 3 Different Biomarkers Related To The Alzheimer’s Disease
Table 4 North America Alzheimer’s Disease Therapeutics And Diagnostics Market 2018-2026 ($ Million)
Table 5 North America Alzheimer’s Disease Therapeutics And Diagnostics Market In Therapeutics By Drugs 2018-2026 ($ Million)
Table 6 North America Alzheimer’s Disease Therapeutics Market In Marketed Drugs 2018-2026 ($ Million)
Table 7 North America Alzheimer’s Disease Therapeutics Market In Pipeline Drugs 2018-2026 ($ Million)
Table 8 North America Alzheimer’s Disease Therapeutics And Diagnostics Market In Disease Stage By Drugs 2018-2026 ($ Million)
Table 9 North America Alzheimer’s Disease Therapeutics Market In Late Stage: Severe Ad 2018-2026 ($ Million)
Table 10 North America Alzheimer’s Disease Therapeutics Market In Early/Middle Stage: Mild To Moderate Ad 2018-2026 ($ Million)
Table 11 North America Alzheimer’s Disease Therapeutics Market In Prodromal Stage 2018-2026 ($ Million)
Table 12 North America Alzheimer’s Disease Therapeutics And Diagnostics Market In Therapeutics By Generic And Branded 2018-2026 ($ Million)
Table 13 North America Alzheimer’s Disease Therapeutics Market In Branded 2018-2026 ($ Million)
Table 14 North America Alzheimer’s Disease Therapeutics Market In Generic 2018-2026 ($ Million)
Table 15 North America Alzheimer’s Disease Therapeutics And Diagnostics Market By Types 2018-2026 ($ Million)
Table 16 North America Alzheimer’s Disease Diagnostics Market In Lumbar Puncture Test 2018-2026 ($ Million)
Table 17 North America Alzheimer’s Disease Diagnostics Market In Positron Emission Tomography 2018-2026 ($ Million)
Table 18 North America Alzheimer’s Disease Diagnostics Market In Electroencephalography 2018-2026 ($ Million)
Table 19 North America Alzheimer’s Disease Diagnostics Market In Magnetic Resonance Imaging 2018-2026 ($ Million)
Table 20 North America Alzheimer’s Disease Diagnostics Market In Computed Tomography 2018-2026 ($ Million)
Table 21 North America Alzheimer’s Disease Diagnostics Market In Other Diagnostics 2018-2026 ($ Million)
Table 22 North America Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figures List
Figure 1 North America Alzheimer’s Disease Therapeutics And Diagnostics Market 2018-2026 ($ Million)
Figure 2 People Suffering From Alzheimer’s Dementia In The United States Of Different Ages 2017 (%)
Figure 3 Rising Health Expenditure In The United States ($ Per Capita)
Figure 4 North America Alzheimer’s Disease Therapeutics And Diagnostics Market In Therapeutics 2018-2026 ($ Million)
Figure 5 North America Alzheimer’s Disease Therapeutics And Diagnostics Market In Diagnostics2018-2026 ($ Million)
Figure 6 Investments In Alzheimer’s Disease Treatment
Figure 7 Alzheimer's Drugs In The Pipeline By Treatment Focus (Number Of Drugs)
Figure 8 Fda-approved Cdx-drug Pairs By Molecular Target
Figure 9 The United States Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 10 Canada Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 11 Market Share Analysis Of Alzheimer’s Disease Therapeutics And Diagnostics Market 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report